<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01459484</url>
  </required_header>
  <id_info>
    <org_study_id>ISG/OS-2</org_study_id>
    <secondary_id>2011-001659-36</secondary_id>
    <nct_id>NCT01459484</nct_id>
  </id_info>
  <brief_title>ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma</brief_title>
  <acronym>ISG/OS-2</acronym>
  <official_title>ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma - Prospective Study (ISG/OS-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italian Sarcoma Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Italian Sarcoma Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to assess the survival in patient with non metastatic
      osteosarcoma of the extremities treated with different chemotherapy protocols, according to
      the expression of ABCB1/P-glycoprotein
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Primary objective is:

      * Overall survival in patient with non metastatic osteosarcoma of the extremities treated
      with different chemotherapy approach (5 drugs vs 3 drugs), according to the expression of
      ABCB1/P-glycoprotein

      The Secondary objectives are:

        -  to assess the survival in patient who over express ABCB1/P-glycoprotein, with
           chemotherapy protocol based on all the 5 available active drugs (Methotrexate,
           cisplatinum, doxorubicine, ifosfamide and mifamurtide)

        -  to assess the survival in patient who do not over express ABCB1/P-glycoprotein
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 23, 2011</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>The patients will be followed in term of Overall Survival, for all the study period (expected average: 7 years)</time_frame>
    <description>The Overall Survival will be evaluated at the end of the study period (5 enrollment years and 2 years - minimum- follow-up from the last enrolled patient)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Events free survival in patient with ABCB1/P-glycoprotein over-expression, and who do not over-express ABCB1/P-glycoprotein</measure>
    <time_frame>after 2 and 3 years from the start of study</time_frame>
    <description>The events free survival will be evaluated by means of interim analysis after 2 and 3 years from the start of study. A further evaluation will be performed at the end of enrollment and after 2 years form the last enrolled patient.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Osteosarcoma</condition>
  <arm_group>
    <arm_group_label>Mifamurtide arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy for patients who over express ABCB1/P-glycoprotein (methotrexate, cisplatinum, doxorubicine, ifosfamide + mifamurtide)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 drugs arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>High grade osteosarcoma treatment for patients who do not over express ABCB1/P-glycoprotein</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifamurtide arm</intervention_name>
    <description>PRE SUGERY TREATMENT:
Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)
POST SURGERY TREATMENT for good responder patients with positive P-GLYCOPROTEIN
Methotrexate 12g/m2 (10 Cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total lenght treatment 44 weeks)
POST SURGERY TREATMENT for poor responder patients with positive P-GLYCOPROTEIN
Methotrexate 12g/m2; Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 ifosfamide 15g/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total lenght treatment 44 weeks)
All the product are used as commercial formulation</description>
    <arm_group_label>Mifamurtide arm</arm_group_label>
    <other_name>Methotrexate</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>doxorubicin</other_name>
    <other_name>ifosfamide</other_name>
    <other_name>mifamurtide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>3 drugs arm</intervention_name>
    <description>High grade osteosarcoma who do not over express ABCB1/P-glycoprotein will be treated with a standard 3-drugs regimen
PRE-SUGERY TREATMENT:
Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)
POST SURGERY TREATMENT:
Methotrexate 12g/m2 (10 cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2
Total lenght 34 weeks
All the product are used as commercial formulation</description>
    <arm_group_label>3 drugs arm</arm_group_label>
    <other_name>methotrexate</other_name>
    <other_name>cisplatin</other_name>
    <other_name>doxorubicine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histology confirmed diagnosis of extremities high grade osteosarcoma

          -  Age â‰¤ 40 years

          -  Localized disease or presence of skip metastasis

          -  Hepatic, renal and bone marrow normal function

          -  LVEF &gt; 50%

          -  No previous surgery and/ or chemotheraputic osteosarcoma treatments,

          -  No more than 4 weeks interval between histological diagnosis and start of chemotherapy

          -  Informed consent to the study participation obtained.

        Exclusion Criteria:

          -  Presence of metastases other than skip metastases

          -  Periosteal Osteosarcoma, parostal osteosarcoma, secondary osteosarcoma,

          -  Medical contra-indication to the drugs foreseen in the protocol,

          -  Subject is pregnant or breast feeding

          -  Mental or social conditions that can compromise a correct adherence to the protocol
             and its procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emanuela Palmerini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Ortopedico Rizzoli</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>I.R.C.C. - Unit of Medical Oncology</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Sanitario Gradenigo</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10153</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto ortopedico Rizzoli</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Meyer</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FONDAZIONE IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori &quot;Fondazione G. Pascale&quot;</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituti Fisioterapici Ospitalieri di Roma</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambin Gesu'</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Infantile Regina Margherita - Unit of Paediatric Oncoematology</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Serra M, Pasello M, Manara MC, Scotlandi K, Ferrari S, Bertoni F, Mercuri M, Alvegard TA, Picci P, Bacci G, Smeland S. May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. Int J Oncol. 2006 Dec;29(6):1459-68.</citation>
    <PMID>17088985</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 19, 2011</study_first_submitted>
  <study_first_submitted_qc>October 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2011</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non metastatic extremities high grade osteosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Mifamurtide</mesh_term>
    <mesh_term>Acetylmuramyl-Alanyl-Isoglutamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

